Prestige Consumer Healthcare Reports Revenue Decline and Acquisition of Pillar5 Pharma

Prestige Consumer Healthcare Inc. reported a decline in financial performance for the three and nine months ended December 31, 2025, as detailed in its latest 10-Q filing. Total revenues for the third quarter amounted to $283.4 million, a decrease of 2.4% from $290.3 million in the same period last year. For the nine-month period, revenues fell by 4.1% to $807.1 million from $841.2 million. The company's net income also decreased, with third-quarter net income reported at $46.7 million, down from $61.0 million a year earlier, and nine-month net income at $136.4 million compared to $164.5 million in the prior year.

The decline in revenue was primarily attributed to decreased sales in key product categories, particularly Eye & Ear Care, Analgesics, and Women's Health, which were partially offset by growth in Oral Care and Gastrointestinal products. The International OTC Healthcare segment also experienced a revenue drop of 7.1%, largely due to reduced sales in the Eye & Ear Care category. Gross profit for the third quarter decreased by 2.3% to $157.4 million, maintaining a gross profit margin of 55.5%. The North American segment's gross profit margin improved slightly to 55.5%, while the International segment's margin fell to 55.9%.

Strategically, Prestige Consumer Healthcare completed the acquisition of Pillar5 Pharma, Inc. on December 18, 2025, enhancing its capabilities in sterile ophthalmic manufacturing. This acquisition was funded through cash and existing credit facilities, and while it is expected to bolster the company's product offerings, its immediate impact on revenues and earnings was deemed not material. The company continues to face challenges from economic uncertainties, including supply chain disruptions and rising input costs, which have affected product availability and pricing.

Operationally, Prestige Consumer Healthcare reported a decrease in its cash and cash equivalents to $62.4 million as of December 31, 2025, down from $97.9 million at the end of the previous fiscal year. The company generated $214.8 million in net cash from operating activities during the nine months, an increase from $189.7 million in the prior year, but faced a significant rise in cash used for investing activities, primarily due to the Pillar5 acquisition. The company’s long-term debt stood at $1.0 billion, with a borrowing capacity of $146.4 million remaining under its asset-based revolving credit facility.

Looking ahead, Prestige Consumer Healthcare anticipates continued volatility in economic conditions, which may impact demand for its products. The company is focused on navigating these challenges while leveraging its brand portfolio and distribution network to drive growth. Management remains committed to maintaining compliance with financial covenants and expects to finance operations through a combination of cash generated from operations and borrowings in the near term.